Lancashire and South Cumbria
Formulary
Formulary
10 Musculoskeletal and joint diseases
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
10-01-02-02 Local corticosteroids injections
| Methylprednisolone Acetate with Lidocaine Depo-Medrone® with lidocaine |
|
Formulary
|
Suspension for injection lidocaine hydrochloride 10mg per 1ml, Methylprednisolone acetate 40mg per 1ml |
|
Links
BSPED Adrenal Insufficiency Consensus Guidelines
LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway- LSCMMG: Primary Care Constipation Guidelines
- MHRA DSU April 2019: Belimumab (Benlysta): increased risk of serious psychiatric events seen in clinical trials
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration
- NHSE: National Patient Safety Alert – Steroid Emergency Card to support early recognition and treatment of adrenal crisis in adults
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA752:Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA806: Belimumab for treating lupus nephritis (terminated appraisal)